Insulet Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Insulet kazanç ve gelirin sırasıyla yıllık 2.5% ve 14.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 0.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 20.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

2.5%

Kazanç büyüme oranı

0.6%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.4%
Gelir büyüme oranı	14.4%
Gelecekteki özkaynak getirisi	20.5%
Analist kapsamı	Good
Son güncelleme	05 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Aug 16

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Jul 15

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Jun 11

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

May 26

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

May 12

Is Insulet (NASDAQ:PODD) A Risky Investment?

Apr 29

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Apr 14

Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)

Mar 31

Insulet: Insulating Patients, Investors Still Have To Wait

Mar 28

Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price

Feb 19

Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?

Jan 22

Insulet: An Interesting, Yet Expensive, Story

Jan 10

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Jan 09

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Dec 27

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Nov 14

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Oct 31

We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt

Oct 01

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Sep 16

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Aug 14

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Jul 31

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Jun 18

Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult

May 22

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Apr 30

Here's Why Insulet (NASDAQ:PODD) Has A Meaningful Debt Burden

Jan 24

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Dec 28

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:PODD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	2,802	367	439	548	19
12/31/2025	2,388	287	357	455	22
12/31/2024	2,016	375	280	397	22
6/30/2024	1,873	395	182	285	N/A
3/31/2024	1,781	234	137	233	N/A
12/31/2023	1,697	206	37	146	N/A
9/30/2023	1,557	120	-15	151	N/A
6/30/2023	1,465	63	-26	152	N/A
3/31/2023	1,368	1	-45	133	N/A
12/31/2022	1,305	5	-38	119	N/A
9/30/2022	1,243	17	-63	43	N/A
6/30/2022	1,178	35	-141	-40	N/A
3/31/2022	1,142	45	-152	-47	N/A
12/31/2021	1,099	17	-191	-68	N/A
9/30/2021	1,037	-29	-199	-26	N/A
6/30/2021	996	-30	-126	44	N/A
3/31/2021	959	9	-120	53	N/A
12/31/2020	904	7	-82	84	N/A
9/30/2020	868	29	-15	114	N/A
6/30/2020	826	18	-25	101	N/A
3/31/2020	777	5	-65	88	N/A
12/31/2019	738	12	-72	98	N/A
9/30/2019	694	17	-74	82	N/A
6/30/2019	653	17	-103	67	N/A
3/31/2019	600	14	-126	47	N/A
12/31/2018	564	3	-126	36	N/A
9/30/2018	529	-13	-130	27	N/A
6/30/2018	500	-17	-93	35	N/A
3/31/2018	486	-23	N/A	59	N/A
12/31/2017	464	-27	N/A	41	N/A
9/30/2017	437	-29	N/A	39	N/A
6/30/2017	410	-30	N/A	19	N/A
3/31/2017	387	-26	N/A	5	N/A
12/31/2016	367	-27	N/A	16	N/A
9/30/2016	347	-34	N/A	-23	N/A
6/30/2016	324	-49	N/A	-17	N/A
3/31/2016	297	-62	N/A	-20	N/A
12/31/2015	264	-62	N/A	-13	N/A
9/30/2015	253	-51	N/A	11	N/A
6/30/2015	256	-44	N/A	7	N/A
3/31/2015	268	-56	N/A	6	N/A
12/31/2014	231	-48	N/A	9	N/A
9/30/2014	285	-49	N/A	1	N/A
6/30/2014	271	-59	N/A	0	N/A
3/31/2014	259	-40	N/A	4	N/A
12/31/2013	247	-45	N/A	3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PODD 'nin tahmini kazanç büyümesi (yıllık 2.5% ) tasarruf oranının ( 2.6% ) altındadır.

Kazançlar ve Piyasa: PODD şirketinin kazançlarının (yıllık 2.5% ) US pazarından (yıllık 15.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: PODD şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: PODD şirketinin gelirinin (yıllık 14.4% ) US pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: PODD şirketinin gelirinin (yıllık 14.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PODD 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 20.5 %)

Insulet Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates increase by 18%

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Consensus EPS estimates increase by 13%

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Price target decreased by 8.0% to US$250

Recent updates

Omnipod 5 App for Iphone Now Fully Available in the United States

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024

Independent Chairman recently sold US$1.1m worth of stock

Independent Chairman notifies of intention to sell stock

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet: Turning More Constructive, Valuations Still Stretched

Here's Why We Think Insulet (NASDAQ:PODD) Is Well Worth Watching

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Now 9.0% overvalued after recent price rise

Now 20% overvalued after recent price rise

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Independent Chairman recently sold US$1.3m worth of stock

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Independent Chairman notifies of intention to sell stock

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

Investor sentiment improves as stock rises 16%

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)

Insulet: Insulating Patients, Investors Still Have To Wait

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Director & Advisor notifies of intention to sell stock

Consensus EPS estimates increase by 18%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price

Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Insulet: An Interesting, Yet Expensive, Story

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Director & Advisor recently sold US$2.5m worth of stock

Director & Advisor notifies of intention to sell stock

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

Price target decreased by 8.0% to US$250

Now 21% undervalued after recent price drop

Insulet Corporation Announces CFO Transition

We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt

Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Consensus EPS estimates increase by 14%

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Insider recently bought US$1.0m worth of stock